We assessed prevalence and risk factors for anal human papillomavirus (HPV) in human immunodeficiency virus (HIV)-positive men who have sex with men (MSM), who are at high-risk of HPV-related anal cancer.
Infection with high-risk types of human papillomavirus (HR-HPV) accounts for approximately 90% of all anal cancer worldwide [1] . Like other human papillomavirus (HPV)-related cancers, anal cancer risk is known to be increased by sexual exposure to HPV infection, most notably via anal intercourse, and to be additionally worsened by human immunodeficiency virus (HIV)-related immunosuppression [2] . Thus, men who have sex with men (MSM) living with HIV suffer a particularly high incidence of anal cancer, which has reached rates >100/100 000 person-years following improvements in survival in the era of combined antiretroviral therapy (cART) [3] [4] [5] . Indeed, anal cancer incidence rates are increasing in several high-income countries [6] , and a substantial proportion of the increase among young males can be attributed to HIV-positive MSM [7] .
Human papillomavirus 16 (HPV16) predominates in HPVpositive anal cancer (approximately 85% [8] ) to a far greater degree than in cervical cancer and hence is uniquely important for prevention of anal cancer. Human papillomavirus 16 is also the most common HPV type in anal cancer in HIV-positive persons, even if the HPV16-positive fraction of HPV types observed in anal cancer is somewhat lower in HIV-positive than in HIV-negative persons [8] .
Although there are some similarities, the natural history of the carcinogenic process from HPV infection to anal cancer is much less well characterized than that for cervical cancer. Although HIV-positive MSM are known to have a high prevalence of anal HPV infection [9] , data on risk factors and natural history of HPV infection in this population are scarcer and come mostly from North American or Australian studies.
The ANRS EP57 APACHES study is an ongoing prospective multicentric study in France with the objective of characterizing the prevalence and evolution of HPV infection and related anal lesions in HIV-positive MSM. All participants undergo regular HPV tests, cytology, high-resolution anoscopy (HRA) and, where appropriate, biopsy. All participants are to be followed up for at least 2 years, and importantly, those detected with high-grade lesions are not treated, but undergo more frequent monitoring (Supplementary Figure 1) . Here we report on the characteristics of this population at baseline and their relationship with anal HR-HPV infection, paying particular attention to HPV16.
METHODS

Recruitment of Study Participants
The study participants were HIV-positive MSM aged ≥35 years attending infectious disease units in 6 University Hospitals across France (Dijon in eastern France, Lyon in the center-east, Marseille and Montpellier in the south, and Paris and Rennes in the northwest) from December 2014 to June 2016. Subjects were ineligible if they had any of the following: history of anal cancer or pelvic radiotherapy; anal intraepithelial neoplasia (AIN) grades 2/3 treated during the last 12 months; any anticancer chemotherapy during the last 24 months; nonaffiliation with the French social insurance system.
After providing written informed consent according to French legislation, eligible subjects were referred to proctologic units in the same city, where all clinical procedures were undertaken.
Data Collection
A structured questionnaire was administered by the practitioner at proctologic sites prior to clinical examination, including detailed data on history of tobacco consumption, sexual habits (number of receptive genito-anal male partners during lifetime and the previous year), and previous anal swab for cytology and/or biopsy. History of CD4 and CD8 cell count, viral load, AIDS-related conditions, and current cART status were obtained from the patient's medical record.
Specimen Testing and Clinical Examination
Two specimens were collected by inserting wetted swabs into the anal canal, 1 for cytology and 1 for HPV DNA tests, before clinical examination. Sterile Anex brushes (Rovers) were used, following the manufacturer's recommendation (ie, inserting 5-7 cm into the anal canal, then slowly extracting with rotation, maintaining firm lateral pressure). Both brushes were transferred to PreservCyt medium (Cytic, Boxbourough, MA), rinsed into the bottom of the vial, and swirled vigorously to release material. The first specimen was used for cytology, the second for HPV. After specimen collection, patients received a standard proctologic examination, including naked eye anoscopy, digital ano-rectal examination, and HRA with the addition of acetic acid and Lugol's iodine staining. Lesions identified by HRA were biopsied and processed for histological examination.
Cytology and Histology
Liquid-based anal cytology slides were prepared and read in local pathology departments that were blinded to HPV results. Cytology results were categorized according to the 2001 Bethesda System terminology: negative; atypical squamous cells of undetermined significance (ASC-US); low-grade squamous intraepithelial lesion (LSIL); atypical squamous cells, cannot exclude HSIL (ASC-H); high-grade squamous intraepithelial lesion (HSIL); and cancer.
Histological slides were prepared and initial histological diagnoses were made in local pathology departments. Final diagnoses were established by consensus of a histopathology review panel. Over 2 days, all slides were concurrently read by 5 pathologists from the 6 APACHES clinics using a multihead microscope; the pathologists were blinded to HPV, cytology and initial histology results. A final consensus diagnosis was reached for each slide, reported as negative, AIN1, AIN2, AIN3, or invasive cancer. Diagnosis of AIN2 required strong uniform p16 immunostaining in addition to hematoxylin and eosin morphological assessment [10] . In case of multiple biopsies, the most severe grade was considered. If no biopsy was taken, histology was considered to be benign, provided the HRA was normal.
A composite cytology-histology endpoint was created [11] , for which a high-grade lesion is defined by presence of ASC-H, HSIL, AIN2, or AIN3 [11] . A composite low-grade lesion is defined by presence of ASCUS, LSIL, or AIN1 (in the absence of a composite high-grade lesion). In the absence of evidence of any lesion, including a normal HRA, composite cytology-histology is considered negative.
Human Papillomavirus DNA Testing and Genotyping
Sample processing and HPV DNA testing and genotyping were performed at the HPV National Reference Centre at the Pasteur Institute, Paris, France. Anal specimens were tested for HPV DNA detection using the Cobas 4800 (Roche Molecular Systems, Alameda, CA). This assay provides partial genotyping, stratifying the results into HPV16, HPV18, and 12 "other HR-HPV" types combined (HPV31/33/35/39/45/51/52/56/58/59/66/68). All Cobas-positive specimens were subsequently genotyped for the same 14 HR-HPV types using the PapilloCheck test system (Greiner BioOne GmbH, Frickenhausen, Germany) as described previously [12] . Detection of non-HR-HPV types by PapilloCheck was ignored.
Statistical Analyses
Prevalence estimates for HPV16, HPV18, and HR-HPV refer to the results of Cobas testing. Type-specific prevalence for HPV31/ 33/35/39/45/51/52/56/58/59/66/68 refers to the results of the PapilloCheck test system. Multiple HR-HPV infection refers to infection with ≥2 of the above 14 HR-HPV types, irrespective of the test. Human papillomavirus prevalence was given as a percentage and corresponding 95% confidence intervals (95% CIs) for binomial proportions. Odds ratios (ORs) and 95% CIs of HPV positivity were calculated according to selected baseline characteristics using unconditional logistic regression models and were adjusted for age, center, and tobacco consumption.
Ethics
The study was approved by the International Agency for Research on Cancer Ethics Committee and according to French regulation by an Ethics Committee (Comité de Protection des Bold values indicate significant associations.
Personnes de Paris Ile de France VI). The study was performed in accordance with Good Clinical Practices and the ethical principles of the Declaration of Helsinki. All participants provided signed informed consent.
RESULTS
Of the 513 HIV-positive MSM enrolled in the ANRS EP57 APACHES study, a valid HPV result using Cobas 4800 was available for 490 participants, and the present analyses are restricted to these men. 
years prior).
Overall prevalence of HPV16 and HR-HPV in cytological specimens was 29.0% (95% CI, 25.1%-33.1%; n = 142) and 70.0% (95% CI, 65.8%-73.9%; n = 343), respectively. Genotyping was performed on the 343 Cobas-positive specimens (of which 16 were not confirmed as positive for any HR-HPV type by PapilloCheck). The prevalence of individual HR-HPV types is presented in Figure 1 . Human papillomavirus 16 was by far the most common HR-HPV type (29.0%; 95% CI, 25.1%-33.1%), followed by HPV68 (16.3%; 95% CI, 13.2%-20.0%) and HPV33 (13.3%; 95% CI, 10.4%-16.6%). Multiple HPV infections were detected in 229 (46.7%) specimens (66.8% of HR-HPV positive samples).
Human papillomavirus 16 and HR-HPV prevalence did not vary significantly by age or study center, nor by number of sexual partners, nor by any HIV-related parameters (Table 1) , including CD4/CD8 ratio, duration of HIV infection, calendar period of first HIV test (before or after 1996), and duration of cART (data not shown). High-risk HPV prevalence was significantly higher in ever smokers (OR, 1.8; 95% CI, 1.2-2.7). Previous history of anal swab and/or biopsy was not associated with HPV16 or HR-HPV prevalence. Prevalence of HPV16 (OR, 4.5; 95% CI, 1.9-10.6) and of HR-HPV (OR, 9.3; 95% CI, 2.9-29.3) was significantly increased among participants with previously diagnosed high-grade lesions compared with those without lesions (Table 1) .
Anal cytology results were unsatisfactory in 11 (2.2%) participants. Of the 479 satisfactory results, 195 (40.7%) were negative, 82 (17.1%) were ASC-US, 165 (34.5%) were LSIL, 6 (1.3%) were ASC-H, and 31 (6.5%) were HSIL ( Figure 2 ). In 267 (54.5%) men, HRA was normal and biopsies were not taken. Histological diagnosis was unsatisfactory in 11 (2.2%) and negative in 59 (12.0%), and the worst histological diagnosis was AIN1 in 102 (20.8%), AIN2 in 23 (4.7%), and AIN3 in 28 (5.7%) (Figure 2) .
Using a composite cytology-histology endpoint, 182 (37.1%) men were classified as negative for lesions, 236 (48.2%) as having low-grade lesions, and 72 (14.7%) as having high-grade lesions ( Figure 2 ). Of note, at the time of writing, none of these high-grade lesions had been treated, but were being monitored every 6 months according to the study protocol ( Supplementary  Figure 1) , and no anal cancers had been diagnosed. Prevalence of HPV16 and HR-HPV by cytology and histology grade, as well as by composite cytology-histology result, is shown in Figure 2 . Prevalence of HPV16 and HR-HPV significantly increased from cytology-negative (23.1% and 56.9%, respectively) to ASC-H (66.7% and 100%, respectively) and HSIL (61.3% and 100%, respectively). A similar increase was observed according to histology result from negative (15.3% and 62.7%, respectively) through AIN1 (29.4% and 80.4%, respectively) to AIN2 (78.3% and 100%, respectively), and AIN3 (53.6% and 96.4%, respectively). Finally, using the composite cytology-histology endpoint, HPV16 and HR-HPV prevalence significantly increased from 19.2% and 53.9%, respectively, for negative lesions, to 62.5% and 98.6%, respectively, for high-grade lesions. Table 2 shows the distribution of HPV16 and non-HPV16 HR-HPV among HPV-positive samples only, according to whether types were found alone (single) or in presence of another HPV type (multiple), by composite lesion grade. Human papillomavirus 16 positivity increased from composite-negative or low-grade (35.7%/35.6%) to high-grade lesion (63.4%), whereas that of non-HPV16 HR-HPV decreased (from 64.3%/64.4% to 36.6%). However, for both HPV16 and non-HPV16 HR-HPV, the majority of HPV infections were detected in the presence of other HR-HPV types. Whereas the proportion of single HPV16 infection was relatively stable regardless of the composite endpoint (5.1%, 4.6%, and 7.0% for composite negative, low-grade, and high-grade, respectively), the frequency of single non-HPV16 HR-HPV decreased with severity of the composite endpoint (38.8% if negative to 14.1% in high-grade). Table 3 shows HPV16 and HR-HPV prevalence among different combinations of cytology and histology outcomes. Within grade of cytology, prevalence of HPV16 increased with severity of histological diagnosis, reaching 68.8% in 16 men with high-grade lesions on both cytology and histology. Prevalence of HPV16 was 75.0% in those with no biopsy taken but with ASC-H/HSIL on cytology (vs 28.2% for those with no biopsy taken and ASCUS/LSIL and 19.4% for those with no biopsy taken and negative cytology). Table 4 shows association between HPV16 prevalence and composite lesion severity by study center, grouped according to frequency of detection of high-grade lesions. Human papillomavirus 16 prevalence discriminated high-grade lesions better in centers detecting >20% composite high-grade lesions (OR, 29.0; 95% CI, 6.0-139) than in those detecting <20% (OR, 4.7; 95% CI, 2.1-10.6). Of note, overall HPV16 prevalence was similar in these 2 groups of centers (Table 4) .
DISCUSSION
Among HIV-positive MSM in the ANRS EP57 APACHES study, anal HPV16 and HR-HPV infection was confirmed to be highly prevalent. It was also shown to be highly consistent across the French centers: of all the variables studied to potentially identify subgroups at higher risk of HPV infection, only smoking was a significant predictor, and weakly so. High-risk HPV prevalence did not differ meaningfully by age, by indicators of sexual behavior, or by any markers related to HIV or immune deficiency among HIV-positive MSM. Human papillomavirus prevalence was also similar between HIV-positive MSM who did not have any previous anal swab for cytology and/or biopsy (over half of study participants) and those had been evaluated in the past. However, a previous history of cytologically or histologically proven high-grade anal lesion was strongly associated with HPV16 and HR-HPV positivity, suggesting persistent infection. Human papillomavirus 16, the most common anal HR-HPV type in this population, predominated over other HR-HPV types to a greater extent than that seen in the cervix [13] but showed a similar lack of association with baseline characteristics. The ANRS EP57 APACHES study population were mainly undergoing cART and presented virological characteristics comparable with other contemporary HIV-positive populations in high-income countries. Indeed, not only were estimates of HPV16 (29.0%) and HR-HPV (70.0%) prevalence consistent across the 6 French cities, but they were also similar to those of a meta-analysis of 11 studies of HIV-positive MSM from other high-income settings [9] -namely, 35.4% for HPV16 and 73.5% for HR-HPV. Taken together, these data suggest a stable estimate for anal HPV prevalence for HIV-positive MSM in high-income settings: approximately one third positive for HPV16 and two thirds positive for HR-HPV.
Given the strong link between HPV16 and anal cancer, HPV16 prevalence can arguably be used as proxy of higher probability of developing anal cancer. Indeed, as expected, HPV16 prevalence increased strongly according to severity of anal diagnosis, both according to the severity of past anal diagnosis prior to inclusion and according to cytological and histological findings at ANRS EP57 APACHES baseline, reaching approximately 60% in high-grade lesions. Similarly, high HPV16 prevalence in ASC-H and HSIL on cytology, as well as in AIN2 and AIN3 on histology, suggests that, with respect to anal cancer risk, each of these 4 diagnoses merit similar consideration. Indeed, a diagnosis of ASC-H, HSIL, and/or AIN2/3 is being used to identify patients requiring more regular anal monitoring in the ANRS EP57 APACHES study protocol (Supplementary Figure 1) . Using similar reasoning, the fact that a composite cytology/histology endpoint offers slightly better discrimination by HPV16 prevalence than cytology or histology alone, as shown previously [9] , suggests that it may offer the most useful stratification of the risk of anal cancer. This is particularly the case when, as at ANRS EP57 APACHES baseline, cytological sampling and HRA are performed simultaneously. Indeed, cytological high-grade lesions were diagnosed among 8 participants who had no biopsy taken during HRA, and their HPV16 prevalence (75.0%) was at least as high as that for histologically confirmed high-grade lesions, suggesting that highgrade lesions can be missed by HRA [14] .
Human papillomavirus 68 was the second most frequently detected HR-HPV type, which was surprising given HPV68's relative rarity in the cervix [13] , and may represent increased of human papillomavirus 16 and non-human papillomavirus 16 high-risk human papillomavirus, by single/multiple infection status  and by grade of composite cytology-histology anal tropism for HPV68. However, taken together with the current absence of evidence of HPV68 involvement in anal cancer [8] , assessment of its causal contribution to anal lesions is made challenging by the very high prevalence of multiple anal HPV infections in HIV-positive MSM [8] . Indeed, this problem of attribution applies to all non-HPV16 HR-HPV types.
Approximately two thirds of HR-HPV-positive participants and three quarters of those with high-grade lesions harbored multiple HR-HPV types. Even most HPV16 was found in the presence of other HR-HPVs. However, prevalence of single infection of non-HPV16 HR-HPV types, but not of single HPV16, decreased from normal to high-grade lesions, suggesting a weaker causal relationship of non-HPV16 HR-HPV with high-grade lesions. Human papillomavirus 18 is the only type other than HPV16 to have been shown to confer higher prospective risk for AIN2/3 versus other HR types [15] , but its prevalence did not particularly stand out from that of other types among HSIL in ANRS EP57 APACHES (data not shown), nor in an international meta-analysis [8] . To better quantify the carcinogenicity of individual HPV types in high-grade lesions of HIV-positive individuals, testing for causal HPV in AIN2/3 biopsies, preferably using laser microdissection, would be necessary [16, 17] . Cytological evaluation was performed in all participants using a brush specifically developed for anal swabs that resulted in a low number (<2.5%) of inadequate results and a prevalence of cytological LSIL (33.7%) and HSIL (6.1%) similar to a meta-analysis of 15 studies of HIV-positive MSM (27.5% and 6.7%, respectively [9] ). In contrast, however, prevalence of histological AIN2/3 (10.4%) was noticeably lower than in 7 previous studies of HIV-positive MSM (23.9% [9] ). High-resolution anoscopy is known to be characterized by a long learning curve to correctly identify lesions to be biopsied [18] . Although all proctologists had theoretical and practical HRA training prior to APACHES, the extent of HRA experience and prevalence of detection of histological AIN2/3 varied by center. Work on quality control and determinants of cytological and histological high-grade lesions in APACHES is ongoing. With respect to the present findings, however, discrimination of lesion severity by HPV16 was best in centers with highest detection of HSIL, lending additional support to HPV16 as a true marker of underlying risk, even if, in practice, detection of lesions is hindered by HRA-related ascertainment problems.
We acknowledge other limitations to this study. The interview on sexual practices was focussed on receptive anal partners and was administered by clinicians, which might explain the inability to detect associations that have been seen in some [19] , although not all [20, 21] , previous studies in MSM and that are known risk factors for anal cancer [22] . Inadequate statistical power might also explain, at least in part, the absence of associations in our study. Indeed, although associations between HPV and CD4 count did not meet statistical significance (as seen in some [23] , but not all [20, 24] previous studies in HIV-positive persons), there did appear to be a weak nonsignificant relationship between lower CD4 count and higher HPV prevalence, which is also a known risk factor for anal cancer [25] . Smoking is a consistent risk factor for cervical cancer [26] , and although rarely found to be associated with anal infection [27] [28] [29] , it is known to be a risk factor for anal cancer among HIV-positive persons [22, 25] . Nevertheless, there still appears to be no patient characteristics to date with clinical utility to stratify HIV-positive MSM at differing HSIL risk [30] , requiring the search for more molecular markers.
Human papillomavirus vaccination is not recommended for boys in France, and although it has been approved for MSM aged <26 years since 2016, it is not expected to have influenced HPV prevalence in the APACHES study. With respect to screening, there is a recommendation for HIV-positive MSM in France to undergo an annual anal examination, but cytology and HRA are not currently approved options [31] . Less than half of our participants had a history of a previous anal swab and/or biopsy, and the 6 ANRS EP57 APACHES centers represent a large majority of those performing anal cytology and HRA in France. Interestingly, the fact that HPV16 prevalence remained almost as high in participants with a historical diagnosis (52.6%) as in those with a concomitant diagnosis (58.7%) of high-grade lesions suggests a need to continue to monitor individuals with a history of high-grade lesions. Of note, 13 of 39 participants with a history of HSIL had a repeat diagnosis of HSIL at ANRS EP57 APACHES baseline. Indeed, there exist little data on the long-term efficacy of detection and treatment of high-grade anal lesions on anal cancer risk to date. ANRS EP57 APACHES is one of the few prospective studies of HPV natural history in the anus. Results presented here will serve as a baseline to assess incidence, persistence, and clearance of type-specific infection and their associated anal lesions. Of particular note, none of the high-grade lesions detected at baseline have been treated but, as for all participants in APACHES, will be regularly monitored. Our cross-sectional data confirm HPV16 as an important determinant of high-grade lesions and corroborate its place as a priority for anal cancer prevention [8] , supporting prospective evidence of a higher AIN2/3 risk for HPV16 versus other HR-HPV types seen in HIV-positive MSM [15] . In the future, prospective analyses of ongoing ANRS EP57 APACHES will help to understand whether HPV16-positive high-grade lesions are also less likely to regress than lesions infected by other types [32] , as a proxy for their risk to evolve to anal cancer.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
